KPC Pharmaceuticals,Inc. (SHA:600422)
China flag China · Delayed Price · Currency is CNY
8.41
-0.08 (-0.94%)
Sep 10, 2026, 1:13 PM CST

KPC Pharmaceuticals,Inc. Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
871.511,2352,2661,5001,6581,574
Trading Asset Securities
839.721,109471.28603.8319.4160.5
Cash & Short-Term Investments
1,7112,3442,7372,1031,9781,735
Cash Growth
-44.47%-14.37%30.13%6.35%14.01%-4.68%
Accounts Receivable
3,1453,5273,8553,2252,6252,011
Other Receivables
204.31188.15123.73797.7595.1169.09
Receivables
3,3493,7163,9794,0222,7202,180
Inventory
1,5511,3831,5401,7721,6811,884
Other Current Assets
308.15281.6299.64250.14388.21381.96
Total Current Assets
6,9207,7248,5558,1486,7666,180
Property, Plant & Equipment
1,1931,2521,2861,3071,2911,361
Long-Term Investments
355.69377.22305.46319.61320.61278.24
Goodwill
1,4971,4991,5031,50391.7391.73
Other Intangible Assets
354.28373.31412.22441.97355.98408.88
Long-Term Deferred Tax Assets
295.68216.31258.28269.12245.6233.83
Long-Term Deferred Charges
289.41270.03237.84237199.07274.49
Other Long-Term Assets
75.8362.0153.1269.83161.1764.98
Total Assets
10,98011,77412,61112,2959,4328,893

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
759.85876.241,056936.78977.121,239
Accrued Expenses
1,2331,5221,8311,5971,2621,117
Short-Term Debt
806.67813.37658.04725.49912.76641.75
Current Portion of Long-Term Debt
85.35109.1961.05199.50.2
Current Portion of Leases
16.2925.9819.2822.4622.5736.07
Current Income Taxes Payable
17.9151.48158.94149.7578.7693.28
Current Unearned Revenue
86.7751.4683.32102.63186.3774.09
Other Current Liabilities
546.58375.561,624329.7350.01284.76
Total Current Liabilities
3,5533,8265,4913,8653,8893,485
Long-Term Debt
690.22683.2446.05107.566099.5
Long-Term Leases
36.6853.4248.5944.2444.7750.47
Long-Term Unearned Revenue
238.72243.24229.92224.09207.58245.34
Long-Term Deferred Tax Liabilities
19.5621.6421.6524.2810.6415.42
Other Long-Term Liabilities
4.974.9328.0375.9777.5856.67
Total Liabilities
4,5434,8325,8654,3414,2893,953

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
756.98756.98756.98757.99758.26758.26
Additional Paid-In Capital
522.1519.66520.622,3271,1611,169
Retained Earnings
3,6154,1143,9813,4903,0712,894
Treasury Stock
----10.42-13.15-26.3
Comprehensive Income & Other
-30.1-28.67-5.29-1.626.3-11.5
Total Common Equity
4,8645,3625,2546,5624,9834,783
Minority Interest
1,5731,5791,4931,392159.5156.98
Shareholders' Equity
6,4376,9416,7467,9545,1434,940
Total Liabilities & Equity
10,98011,77412,61112,2959,4328,893

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
1,6351,685833.02900.741,140828
Net Cash (Debt)
76.01658.371,9041,203838.19906.76
Net Cash Growth
-94.42%-65.42%58.33%43.47%-7.56%-9.49%
Net Cash Per Share
0.100.872.531.581.121.20
Filing Date Shares Outstanding
756.98756.98756.98757.11758.13758.26
Total Common Shares Outstanding
756.98756.98756.98757.99758.26758.26
Working Capital
3,3673,8983,0644,2832,8782,695
Book Value Per Share
6.437.086.948.666.576.31
Tangible Book Value
3,0133,4903,3384,6174,5354,283
Tangible Book Value Per Share
3.984.614.416.095.985.65
Buildings
1,3341,3381,3251,2621,1371,136
Machinery
1,0651,0591,0581,011988.66980.07
Construction In Progress
108.34100.476.46100.5164.6543.51